Cite
APA Citation
Staber, P. B., Jurczak, W., Greil, R., Vucinic, V., Middeke, J. M., Montillo, M., Munir, T., Neumeister, P., Schetelig, J., Stilgenbauer, S., Striebel, F., Dirnberger-Hertweck, M., Weirather, J., Brugger, W., Kelemen, P., Wendtner, C., & Woyach, J. A. (2021). tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. Leukemia & lymphoma, 62(14), 3440–3451. http://access.bl.uk/ark:/81055/vdc_100147039000.0x000036